Isoniazid Solution and Singulair (Montelukast Tablets)
Determining the interaction of Isoniazid Solution and Singulair (Montelukast Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Isoniazid may increase the blood levels and effects of montelukast. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects such as headache, fever, sore throat, cough, abdominal pain, diarrhea, earache, runny nose, or uncommon but serious behavior and mood changes (e.G., agitation including aggressive behavior or hostility; bad or vivid dreams; depression; confusion; difficulty concentrating; anxiety; hallucinations; irritability; memory impairment; restlessness; sleep walking; suicidal thoughts and actions; tremor; trouble sleeping). It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 2C8 and/or 2C9 may increase the plasma concentrations of montelukast, which is metabolized by these isoenzymes in addition to CYP450 3A4. When montelukast was administered with the potent CYP450 2C8/2C9 inhibitor gemfibrozil, montelukast systemic exposure (AUC) increased by 4.4-fold. The addition of itraconazole, a potent CYP450 3A4 inhibitor, to gemfibrozil and montelukast did not further increase the AUC of montelukast. Administration of itraconazole alone with montelukast also resulted in no significant increase in the AUC of montelukast, which would suggest that montelukast is primarily metabolized by CYP450 2C8 and 2C9 in vivo.
MANAGEMENT: According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil. However, it may be advisable to monitor patients for potentially increased adverse effects during coadministration with gemfibrozil or other CYP450 2C8/2C9 inhibitors.
- "Product Information. Singulair (montelukast)." Merck & Co, Inc, West Point, PA.
- Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):
Generic Name: isoniazid
Brand name: Nydrazid
Synonyms: Isoniazid
Generic Name: montelukast
Brand name: Singulair
Synonyms: Singulair
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Isoniazid Solution-Sinografin
- Isoniazid Solution-Sinus & Allergy PE
- Isoniazid Solution-Sinus Congestion and Pain Daytime Cool Ice
- Isoniazid Solution-Sinus Nasal Spray
- Isoniazid Solution-Sinus Pain & Pressure
- Isoniazid Solution-Sinutab Ex-Strength
- Singulair (Montelukast Tablets)-Isoniazid Syrup
- Singulair (Montelukast Tablets)-Isoniazid Tablets
- Singulair (Montelukast Tablets)-Isoniazid, pyrazinamide, and rifampin
- Singulair (Montelukast Tablets)-Isoproterenol
- Singulair (Montelukast Tablets)-Isoproterenol Hydrochloride
- Singulair (Montelukast Tablets)-Isoproterenol Injection